GLP-1 Lawsuit Tracker
Over $6 billion in active GLP-1 litigation is pending in 2026, including gastroparesis injury claims against Novo Nordisk, 130+ patent infringement lawsuits against compounders, and FTC investigations into deceptive marketing. This tracker monitors major legal developments that may affect GLP-1 patients and providers.
Last updated: April 2026. This is a summary of publicly reported litigation — not legal advice.
Ozempic/Wegovy Gastroparesis & GI Injury Claims
MDL ActiveThousands of individual claims alleging Ozempic and Wegovy caused severe gastroparesis (stomach paralysis), bowel obstruction, and other serious GI injuries beyond what was disclosed in prescribing information. Consolidated into multibellwether litigation.
Novo Nordisk vs. Compounding Pharmacies (Patent Infringement)
Active across 40+ statesNovo Nordisk filed 130+ lawsuits against compounding pharmacies selling compounded semaglutide, alleging patent infringement and patient safety violations. Many resulted in settlements or pharmacy closures.
Eli Lilly vs. Compounding Pharmacies (Tirzepatide)
ActiveEli Lilly pursuing similar patent enforcement actions against pharmacies compounding tirzepatide (the active ingredient in Mounjaro/Zepbound) after FDA ruled tirzepatide was never in shortage.
FTC Enforcement Against Deceptive GLP-1 Marketing
Ongoing investigationsThe FTC is investigating multiple telehealth companies for deceptive marketing practices related to GLP-1 medications, including false efficacy claims, hidden pricing, and misleading before/after imagery.
State AG Actions Against Compounded GLP-1 Sellers
Active in 12+ statesState attorneys general in Texas, California, Florida, and 9+ other states pursuing enforcement against companies selling compounded GLP-1 medications without proper licensing or making unsubstantiated health claims.
What This Means for Patients
If you experienced severe GI side effects
If you developed gastroparesis, severe stomach paralysis, bowel obstruction, or other serious GI injuries while taking Ozempic, Wegovy, Mounjaro, or Zepbound, you may be eligible to join the MDL. Consult a personal injury attorney specializing in pharmaceutical litigation.
If your compounded medication was discontinued
Many compounding pharmacies shut down or stopped offering semaglutide after FDA enforcement and Novo Nordisk lawsuits. If your provider can no longer supply your medication, see our provider rankings for legitimate alternatives offering brand-name or reformulated compounded options.
How to verify your provider
Use our Safety Checker to verify any provider's FDA compliance status before enrolling. Check for active warning letters, pharmacy licensing, and trust scores.